

23 November 2021

Presentations and recording now available

First #Webinar Thematic Network by the Interest Group on Supranational Biolaw of the European Association of Health Law on "EU values and health digitalization: the inclusion of vulnerable groups"

The EU Health Policy Platform hosted the webinar "EU values and health digitalization: the inclusion of vulnerable groups" by the Thematic Network leader Interest Group on Supranational Biolaw of the European Association of Health Law, on Monday 22 November from 11.00 to 12.30 CET, Brussels time.

- The **presentations** are available on the EU Health Policy Platform – Agora network. To access, please [register first](#) (use/create your EU login). Once your request of access has been approved, you will receive a confirmation email. You will then be able to have a look to the presentations, [available in this post](#) on the Platform.
- **Watch the recording**, available under this [link](#). Use this password to watch it: @HPP_webinar2021

This webinar included three presentations.

- 1) The first one focused on the perspective of EU values in the field of health, on the questions of how and why health as a fundamental value should also be inclusive and equitable within the EU. Conversely, this included how the pharmaceutical strategy could (should) promote policy options based not only on the ethos of non-discrimination, but also on solidarity, especially concerning the increasing role of digital health.
- 2) Embracing the overarching theme of inclusion and solidarity, the second presentation focused on the use of data driven technologies to represent otherwise underrepresented groups from society. Artificial intelligence and real-world evidence represent opportunities for research and development strategies to be more inclusive and representative of diverse population groups, for instance in terms of age, gender or race.
- 3) The third presentation was dedicated to the specific case of rare diseases. As has been observed in the revision process of the regulation on orphan medicinal products, market dynamics remain insufficient to drive research and developments initiatives towards unmet medical needs. For the digital transition in health to be inclusive, data-driven technologies should be used and adapted to the specific challenges of the development of medicines for rare diseases